Chris Howerton
Stock Analyst at Jefferies
(2.68)
# 1,935
Out of 5,124 analysts
71
Total ratings
47.27%
Success rate
19.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Hold | $5 → $7.5 | $7.03 | +6.69% | 12 | Dec 31, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $79 → $125 | $67.78 | +84.42% | 3 | Dec 11, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.80 | +37.93% | 5 | Jan 2, 2025 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.96 | +104.08% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.17 | +360.83% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.53 | +22,906.54% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $17.81 | +3,942.67% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.48 | -66.22% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $23.17 | -56.84% | 1 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $21.54 | -48.93% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $25.27 | +58.29% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $37.64 | +62.06% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $148.79 | -39.51% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.58 | +3,341.75% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $26.43 | +149.72% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.71 | +285.29% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.03 | +1,938.83% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.61 | +3,498.89% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $26.70 | -21.35% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $14.44 | +3,916.62% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.64 | +3,558.54% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $70.20 | -77.21% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $87.26 | -69.06% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $3.20 | +37,400.00% | 1 | May 26, 2020 |
Vanda Pharmaceuticals
Dec 31, 2025
Maintains: Hold
Price Target: $5 → $7.5
Current: $7.03
Upside: +6.69%
Structure Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $79 → $125
Current: $67.78
Upside: +84.42%
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.80
Upside: +37.93%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.96
Upside: +104.08%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.17
Upside: +360.83%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.53
Upside: +22,906.54%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $17.81
Upside: +3,942.67%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.48
Upside: -66.22%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $23.17
Upside: -56.84%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $21.54
Upside: -48.93%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $25.27
Upside: +58.29%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $37.64
Upside: +62.06%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $148.79
Upside: -39.51%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.58
Upside: +3,341.75%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $26.43
Upside: +149.72%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.71
Upside: +285.29%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.03
Upside: +1,938.83%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.61
Upside: +3,498.89%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $26.70
Upside: -21.35%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $14.44
Upside: +3,916.62%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.64
Upside: +3,558.54%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $70.20
Upside: -77.21%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $87.26
Upside: -69.06%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $3.20
Upside: +37,400.00%